Skip to content

bioAffinity Technologies, Inc.

BIAF· NasdaqCore metricsCIK 1712762

Commercial physical & biological research16 peers

Last sale
Nov 12, 2026 · -7.21%
Market cap
$4.33M
1.82M shares
Filings
401
$1.07M
Q3 2026−34.2% FY25 yoy
-$5.28M
Q3 2026N/M FY25 yoy
-$3.51M
Q3 2026N/M FY25 yoy
-$10.47M
Q3 2026derivedN/M FY25 yoy
-$5.89
Q3 2026N/M FY25 yoy
$2.55M
Q3 2026+483.5% FY25 yoy
$4.33M
—
0.8×
1.1×
-300.89%
—

Twelve months to Sep 30, 2026 · derived

Price

$2.38+11.21%+$0.24past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$6.16MFY 2025
$9.36M0FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$6,161,959reported
FY 20242024-12-31$9,362,022reported
FY 20232023-12-31$2,532,499reported
FY 20222022-12-31$4,803reported

Segments

Products
Revenue by Products, FY2022 to FY2025FY2022Other Revenues · FY2022 · $4.80KFY2023Health Care, Patient Service · FY2023 · $2.20MHistology Service Fees · FY2023 · $272.66KMedical Director Fees · FY2023 · $19.32KOther Revenues · FY2023 · $21.52KDepartment of Defense Observational Studies · FY2023 · $19.44KDiagnostic Research And Development · FY2023 · $19.44KDepartment of Defense Observational Studies · FY2023 · $19.44KOther · FY2023 · $291.98KFY2024Health Care, Patient Service · FY2024 · $8.18MHistology Service Fees · FY2024 · $1.10MMedical Director Fees · FY2024 · $66.58KOther Revenues · FY2024 · $7.37KDepartment of Defense Observational Studies · FY2024 · $8.65KDiagnostic Research And Development · FY2024 · $8.65KFY2025Health Care, Patient Service · FY2025 · $4.97MHistology Service Fees · FY2025 · $1.12MMedical Director Fees · FY2025 · $68.27KOther Revenues · FY2025 · $4.86KDepartment of Defense Observational Studies · FY2025 · $577.00Diagnostic Research And Development · FY2025 · $577.00
LineFY2025ShareChange
Health Care, Patient Service$4.97M81%−39.2%
Histology Service Fees$1.12M18%+1.2%
Medical Director Fees$68.27K1.1%+2.5%
Other Revenues$4.86K0.1%−34.1%
Department of Defense Observational Studies$577.000.0%−93.3%
Diagnostic Research And Development$577.000.0%−93.3%
Department of Defense Observational Studies———
Other———
Total$6.16M

From the 10-K filed Mar 16, 2026BIAF

Commercial physical & biological research

bioAffinity Technologies, Inc. is the 10th largest of the 17 covered companies the SEC files under this code, by revenue. SIC 8731

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

bioAffinity Technologies, Inc. · CIK 1712762 · Engraved from SEC EDGAR